약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 3.

Table. 3.

Incremental cost-effectiveness ratio of combination therapy with proton pump inhibitor

Author Time horizon Patient ICER
De Groot et al. (2013)10) Lifetime No previous cardiovascular events
Average GI bleeding risk $14,349.63/QALY
High GI bleeding risk $14,537.45/QALY
Having a history of ACS
Average GI bleeding risk $783.29/QALY
High GI bleeding risk -
Earnshaw et al. (2011)11) Lifetime no previous ACS, age=45, healthy male, 10% CHD risk and annual GI bleeding risk of 8 in 10 00 $444,077.00/QALY
Saini et al. (2008>)13) Lifetime 65 year-old patients with CHD using ASA for secondary prevention
UGIB Risk 3X (50 years) $9,118.00/LY
UGIB Risk 3X (65 years) (Dominated)
UGIB Risk 3X (80 years) (Dominated)
Average UGIB Risk (50 years) $79,955.00/LY
Average UGIB Risk (60 years) $40,090.00/LY
Average UGIB Risk (80 years) $16,887.00/LY
Saini et al. (2011)14) Lifetime 50 year-old patients with no risk factors for upper GI bleeding, using ASA for secondary prevention $19,001.00/LY
Chau et al. (2017)9 5 years 60- to 69-year-old $18,453.90/QALY
70 - to 79-year-old $20,411.42/QALY
80- to 89-year-old $89,210.06/QALY
Takabayashi et al. (2015)12) 30 years 55 year-old (starting age) patients in Japan with histories of upper gastrointestinal ulcers and ischemic stroke using ASA for secondary prevention
2%; branded PPI cost $12,229.65/LY
2%; generic PPI cost (Dominated)

ACS, acute coronary syndrome; ASA, aspirin; CHD, coronary heart disease; GI, gastrointestinal bleeding; ICER, incremental cost-effectiveness ratio; PPI, proton pump inhibitors; UGIB, upper gastrointestinal bleeding

Yakhak Hoeji 2022;66:292-301 https://doi.org/10.17480/psk.2022.66.5.292
© 2022 Yakhak Hoeji